A case for cautious optimism

First Page		Document Content
Date: 2010-08-24 11:17:29 Pharmacology Neurological disorders Pharmaceutical industry Drug discovery Clinical research Novartis Fragile X syndrome Clinical trial Latrepirdine Health Medicine Pharmaceutical sciences		A case for cautious optimism Add to Reading List Source URL: www.nature.com Download Document from Source Website File Size: 117,83 KB Share Document on Facebook

	SL-35: Oncology Phenotypic Screening. Macrocycles. Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents in oncology drug discovery [1]. For exa DocID: 1voSH - View Document
	Seminars on Drug Discovery & Development Wednesdays 17::00, Lecture Hall 1, Pharmazentrum, Klingelbergstrasse 50, Basel Feb 24, 16 Prof. Dr. G. Klebe, Institute of Pharmaceutical Chemistry, Philipps-University Mar DocID: 1vnYL - View Document
	THE SCIENCE OF BETTER MEDICINES The Harvard Program in Therapeutic Science (HiTS) is building partnerships and developing new ideas and technologies to advance drug discovery and precision medicine. DocID: 1vnKo - View Document
	Scientific Program conferenceseries.com 3rd International Conference and Expo on Drug Discovery & Designing DocID: 1vngF - View Document
	5th CDDD Meeting COMPUTATIONALLY DRIVEN DRUG DISCOVERY November 16-17, 2017 \| IFOM, Milan - Italy DocID: 1vkVj - View Document